Comparative Pharmacology
Head-to-head clinical analysis: BONIVA versus ZOLEDRONIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BONIVA versus ZOLEDRONIC ACID.
BONIVA vs ZOLEDRONIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits bone resorption via binding to hydroxyapatite and inhibiting osteoclast activity.
Inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite and inhibiting farnesyl pyrophosphate synthase, disrupting the mevalonate pathway.
150 mg orally once monthly; 2.5 mg orally once daily also approved but less commonly used. Administer on empty stomach with plain water (6-8 oz) at least 60 minutes before first food, beverage, or other medications. Do not lie down for 60 minutes after administration.
5 mg intravenously over at least 15 minutes once yearly for Paget disease or osteoporosis; 4 mg intravenously over at least 15 minutes every 3-4 weeks for hypercalcemia of malignancy or multiple myeloma/bone metastases.
None Documented
None Documented
Clinical Note
moderateZoledronic acid + Deferasirox
"The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Deferasirox."
Clinical Note
moderateTiaprofenic acid + Zoledronic acid
"The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Zoledronic acid."
Clinical Note
moderateCarprofen + Zoledronic acid
"The risk or severity of adverse effects can be increased when Carprofen is combined with Zoledronic acid."
Clinical Note
moderateTerminal half-life: 10-60 hours (clinical relevant); long terminal half-life (120-720 hours) due to slow dissociation from bone, supports weekly dosing.
Terminal half-life is approximately 146 hours (6 days), reflecting slow release from bone; clinical effect persists beyond this due to prolonged binding to hydroxyapatite.
Renal: ~50-60% unchanged in urine; biliary/fecal: ~40-50% eliminated via feces, primarily as unchanged drug.
Primarily renal (30-40% unchanged in urine over 24h, accounting for ~50% of total clearance); negligible biliary or fecal elimination (<1%).
Category C
Category D/X
Bisphosphonate
Bisphosphonate
Thalidomide + Zoledronic acid
"The risk or severity of adverse effects can be increased when Thalidomide is combined with Zoledronic acid."